FDA Clears Legend Biotech's LB2501, A CAR-T Therapy Built Inside The Body, For U.S. Testing

Legend Biotech plans a U.S. Phase 1/2 study of LB2501 in relapsed or refractory B-cell cancers, without lymphodepleting chemotherapy.

Share
FDA Clears Legend Biotech's LB2501, A CAR-T Therapy Built Inside The Body, For U.S. Testing

The U.S. Food and Drug Administration has cleared the investigational new drug application for LB2501, Legend Biotech said Thursday in a release furnished to the SEC on Form 6-K. The therapy is designed to make CAR-T cells, a type of engineered immune cell, inside the patient rather than in a lab.

What the release says

LB2501 is an off-the-shelf, single-infusion therapy that generates CAR-T cells carrying a receptor aimed at two targets, CD19 and CD20. The company calls it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance, a description it applies to itself.

A planned U.S. Phase 1/2 study will assess safety, tolerability, pharmacokinetics and preliminary efficacy in relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma. The release says the therapy is being evaluated without lymphodepleting chemotherapy.

LB2501 is already in an ongoing Phase 1, open-label study in China in patients with relapsed or refractory B-cell malignancies, the release says. That study is assessing safety, tolerability and preliminary efficacy.

The therapy is built on Legend's proprietary TaVec platform and uses an engineered, replication-incompetent lentiviral vector designed to selectively transduce T cells. Once transduced, the cells produce a receptor that targets both CD19 and CD20. The company says the dual approach is intended to help address antigen escape and other possible routes of treatment resistance.

What it changes

Making the cells in the body could potentially avoid several manufacturing steps required for conventional autologous CAR-T therapies, the company says. Autologous means made from the patient's own cells.

Chief Executive Officer Ingrid Zhang said: "We believe in vivo CAR-T represents the next frontier of cell therapy." She called the clearance "an important step" for LB2501 and the broader in vivo platform.

The release says B-cell non-Hodgkin lymphoma accounts for 90% of all malignant lymphomas, and that patients with relapsed or refractory disease, particularly after multiple lines of therapy, often face limited options.

Market data showed Legend's U.S.-listed shares closed at $19.04 on Wednesday, up 6.49% from the prior session, before the announcement. Its market value was $3.7 billion.

The U.S. trial is still planned; the release gives no start date, and the China study remains ongoing.

Sources